Letrozole CAS : 112809-51-5

Product Details:

Alias: Femara

CAS No.: 112809-51-5

MF: C17H11N5

MW: 285.3

Purity: 98.0~102.0%

Appearance: White or Almost White Crystalline Powder

Place of Origin: China

Standard: USP/BP

Usage: Used as API in Treatment of breast disease

Applications:

Intermediate. It self as an anabolic hormone drugs, can promote protein synthesis and inhibiting protein dysplasia, and can lower blood cholesterol, reduce calcium phosphorus excretion and reduce bone marrow suppression, promoting development, promote tissue freshmen and granulation. Caused by long-term use of adrenal cortical hormone have prevention and protection against the adrenal cortex hypofunction.

Second only to Dianabol (methandrostenolone) as a bodybuilding anabolic steroid. Additionally, it has had considerable medical importance particularly for treatment of anemia, and more recently to help maintain lean body mass in HIV-compromised patients.

Alienation can promote protein synthesis and inhibiting protein, and can lower blood cholesterol, reduce calcium phosphorus excretion and reduce bone marrow suppression, promote development and so on.

Letrozole is approved by the United States Food and Drug Administration for the treatment of local or metastatic breast cancer that is hormone receptor positive or has an unknown receptor status in postmenopausal women.

Letrozole is intended for use only by women who are no longer of childbearing age. Possible candidates must have already ceased to menstruate. It is often used in patients who have already undergone other cancer treatments, such as radiation, chemotherapy, and used other cancer drugs, like tamoxifen. This nonsteroidal aromatase inhibitor may help prevent any remaining cancer cells from spreading.